Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011667 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
- 20
- Study locations
NCT07011667: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT07011667 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 609 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07011667, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.
Primary Outcome
Measured as percentage change.
Conditions Studied
Interventions
- DRUG CagriSema (Cagrilintide B and Semaglutide I)
- DRUG Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Study Locations (20)
Florida
- Northeast Research Institute - Fleming Island
- Jacksonville Ctr For Clin Res - Jacksonville
- South Broward Research LLC - Miramar
- Florida Inst For Clin Res LLC - Orlando
- Oviedo Medical Research, LLC - Oviedo
- Cnt for Diab,Obes, and Metab - Pembroke Pines
California
- FDRC - Costa Mesa
- Linda Vista Health Care Ctr - San Diego
- Diablo Clinical Research, Inc. - Walnut Creek
Illinois
- Great Lakes Clinical Trials - Chicago
- Endeavor Health - Skokie
- Evanston Premier Hlthcr Res - Skokie
Georgia
- Hope Clin Res & Wellness - Conyers
- Endocrine Research Solutions - Roswell
Missouri
- StudyMetrix Research LLC - City of Saint Peters
- Amicis Centers of Clinical Research - St Louis
Indiana
- Midwest Inst For Clin Res - Indianapolis
Iowa
- Iowa Diab & Endo Res Center - West Des Moines
Michigan
- Northern Pines Hlth Ctr, PC - Buckley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2028-10-17 |
| Phase | Phase 3 |
What the registry record for NCT07011667 still lists
NCT07011667 is an interventional study that assigns participants to a tested intervention. The registered 609 participants enrollment target is mid-sized for trials with a published cap, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which CagriSema (Cagrilintide B and Semaglutide I) is the first listed.
NCT07011667 names 20 study sites across 9 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT07011667 about?
NCT07011667 is a clinical study titled "A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term". This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get Cagr...
What is the current status of trial NCT07011667?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2025-06-03. Estimated completion is 2028-10-17.
What conditions does trial NCT07011667 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07011667?
The interventions under investigation include: CagriSema (Cagrilintide B and Semaglutide I) (DRUG), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) (DRUG).
Who is sponsoring clinical trial NCT07011667?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011667 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07011667's enrollment target sits among peer trials
609 115th of 1053 higher than 939 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT05838638 · 610 participants · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI